{
    "clinical_study": {
        "@rank": "125962", 
        "arm_group": {
            "arm_group_label": "dabigatran etexilate", 
            "arm_group_type": "Experimental", 
            "description": "single dose treatment with dabigatran oral solution"
        }, 
        "brief_summary": {
            "textblock": "Study will assess PK/PD parameters and safety and tolerability of the study medication in\n      this age group"
        }, 
        "brief_title": "Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Venous Thromboembolism", 
        "condition_browse": {
            "mesh_term": [
                "Thromboembolism", 
                "Venous Thromboembolism", 
                "Venous Thrombosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. males or females 1 to less than 2 years of age\n\n          2. objective diagnosis of primary venous thromboembolism\n\n          3. completion of planned treatment course with low molecular weight heparin or oral\n             anticoagulant for primary venous thromboembolism\n\n          4. written informed consent by parent (legal guardian) and patient assent (if\n             applicable)\n\n        Exclusion criteria:\n\n          1. weight less than 10 kg\n\n          2. conditions associated with increased risk of bleeding\n\n          3. patients who have any condition that would not allow safe participation in study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "2 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01773174", 
            "org_study_id": "1160.145"
        }, 
        "intervention": {
            "arm_group_label": "dabigatran etexilate", 
            "description": "age & weight adjusted equivalent of adult dose", 
            "intervention_name": "dabigatran etexilate", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Newark", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }, 
                    "name": "1160.145.00007 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "1160.145.0006 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "1160.145.00001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Single Dose Open-label PK/PD, Safety and Tolerability Study of Dabigatran Etexilate Mesilate Given at the End of Standard Anticoagulant Therapy in Children Aged 1 Year to Less Than 2 Years in Conjunction With Study 1160.89", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Ecarin clotting time (ECT)", 
                "safety_issue": "No", 
                "time_frame": "one day"
            }, 
            {
                "measure": "Factor IIa inhibition", 
                "safety_issue": "No", 
                "time_frame": "one day"
            }, 
            {
                "measure": "Incidence of all bleeding events", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "measure": "Incidence of all adverse events", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "measure": "Plasma concentrations of total dabigatran", 
                "safety_issue": "No", 
                "time_frame": "one day"
            }, 
            {
                "measure": "Plasma concentrations of free dabigatran", 
                "safety_issue": "No", 
                "time_frame": "one day"
            }, 
            {
                "measure": "Plasma concentrations of BIBR 1048 BS (Base)", 
                "safety_issue": "No", 
                "time_frame": "one day"
            }, 
            {
                "measure": "Plasma concentrations of BIBR 951 BS", 
                "safety_issue": "No", 
                "time_frame": "one day"
            }, 
            {
                "measure": "Plasma concentrations of BIBR 1087 SE (Acid)", 
                "safety_issue": "No", 
                "time_frame": "one day"
            }, 
            {
                "measure": "Activated prothrombin time (aPTT)", 
                "safety_issue": "No", 
                "time_frame": "one day"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01773174"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Global assessment of tolerability will be summarized across all patients in the treated set", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "measure": "Patient assessment of taste will be summarized across all patients in the treated set", 
                "safety_issue": "No", 
                "time_frame": "one day"
            }, 
            {
                "measure": "Changes in laboratory and clinical parameters", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}